Welcome to ERAD Therapeutics Inc. (ERAD), a private clinical stage drug company dedicated to developing therapeutics for the treatment of Rare Genetic Diseases. With a focus on Tay-Sachs Disease, Gaucher Disease, and other lysosomal storage diseases, ERAD aims to address the tremendous unmet clinical need for these orphan designated diseases.

One of ERAD's key strengths lies in their ability to target both the neurological and non-neurological manifestations of these diseases. By crossing the Blood-Brain-Barrier and delivering the necessary enzymes to all cells in the human body, ERAD's innovative drug delivery system offers hope where there are currently no therapeutic options available. Furthermore, ERAD recognizes the market opportunity associated with these conditions.

With no current treatment for Tay-Sachs Disease Type 1 and a Gaucher Disease market that exceeds $1. 6 billion per year and is growing, ERAD is well-positioned to make a significant impact. Backed by an experienced management team and Board of Directors, ERAD Therapeutics Inc